Acumen Pharmaceuticals Analyst Ratings
Acumen Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/20/2023 | 88.93% | B of A Securities | → $14 | Reinstates | → Buy |
07/17/2023 | 75.44% | Cantor Fitzgerald | → $13 | Reiterates | Overweight → Overweight |
07/17/2023 | 102.43% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
05/18/2023 | 75.44% | Cantor Fitzgerald | → $13 | Initiates Coverage On | → Overweight |
03/28/2023 | 75.44% | Credit Suisse | $16 → $13 | Maintains | Outperform |
03/28/2023 | 102.43% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
02/02/2023 | 102.43% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
11/15/2022 | 115.92% | Credit Suisse | $17 → $16 | Maintains | Outperform |
10/05/2022 | 196.9% | BTIG | $15 → $22 | Maintains | Buy |
07/15/2022 | 102.43% | BTIG | → $15 | Initiates Coverage On | → Buy |
06/30/2022 | 102.43% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
03/29/2022 | 129.42% | Credit Suisse | $26 → $17 | Maintains | Outperform |
01/21/2022 | 88.93% | B of A Securities | $16 → $14 | Upgrades | Neutral → Buy |
07/26/2021 | 264.37% | UBS | → $27 | Initiates Coverage On | → Buy |
07/26/2021 | 169.91% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
07/26/2021 | 250.88% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
07/26/2021 | 264.37% | Stifel | → $27 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
07/20/2023 | 88.93% | B of A 证券 | → 14 美元 | 恢复 | → 购买 |
07/17/2023 | 75.44% | 坎托·菲茨杰拉德 | → 13 美元 | 重申 | 超重 → 超重 |
07/17/2023 | 102.43% | HC Wainwright & Co. | → 15 美元 | 重申 | 购买 → 购买 |
05/18/2023 | 75.44% | 坎托·菲茨杰拉德 | → 13 美元 | 启动覆盖开启 | → 超重 |
03/28/2023 | 75.44% | 瑞士信贷 | 16 美元 → 13 美元 | 维护 | 跑赢大盘 |
03/28/2023 | 102.43% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
02/02/2023 | 102.43% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
11/15/2022 | 115.92% | 瑞士信贷 | 17 美元 → 16 美元 | 维护 | 跑赢大盘 |
2022年5月10日 | 196.9% | BTIG | 15 美元 → 22 美元 | 维护 | 购买 |
07/15/2022 | 102.43% | BTIG | → 15 美元 | 启动覆盖开启 | → 购买 |
06/30/2022 | 102.43% | HC Wainwright & Co. | → 15 美元 | 启动覆盖开启 | → 购买 |
2022 年 3 月 29 日 | 129.42% | 瑞士信贷 | 26 美元 → 17 美元 | 维护 | 跑赢大盘 |
01/21/2022 | 88.93% | B of A 证券 | 16 美元 → 14 美元 | 升级 | 中性 → 买入 |
2021 年 7 月 26 日 | 264.37% | 瑞银(UBS) | → 27 美元 | 启动覆盖开启 | → 购买 |
2021 年 7 月 26 日 | 169.91% | B of A 证券 | → 20 美元 | 启动覆盖开启 | → 中立 |
2021 年 7 月 26 日 | 250.88% | 瑞士信贷 | → 26 美元 | 启动覆盖开启 | → 跑赢大盘 |
2021 年 7 月 26 日 | 264.37% | Stifel | → 27 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Acumen Pharmaceuticals (ABOS)?
Acumen Pharmicals(ABOS)的目标价格是多少?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by B of A Securities on July 20, 2023. The analyst firm set a price target for $14.00 expecting ABOS to rise to within 12 months (a possible 88.93% upside). 9 analyst firms have reported ratings in the last year.
A Securities于2023年7月20日公布了Acumen Pharmicals(纳斯达克股票代码:ABOS)的最新目标股价。该分析公司将目标股价定为14.00美元,预计ABOS将在12个月内升至12个月内(可能上涨88.93%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
分析师对Acumen Pharmicals(ABOS)的最新评级是多少?
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by B of A Securities, and Acumen Pharmaceuticals their buy rating.
Acumen Pharmicals(纳斯达克股票代码:ABOS)的最新分析师评级由B of A Securities提供,Acumen Pharmicals提供买入评级。
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Acumen Pharmicals(ABOS)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on July 20, 2023 so you should expect the next rating to be made available sometime around July 20, 2024.
分析师在进行了广泛的研究(包括浏览公开财务报表、与Acumen Pharmicals的高管和客户交谈以及听取财报电话会议)后得出了股票评级。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Acumen Pharmicals的最后一次评级是在2023年7月20日提交的,因此你应该预计下一个评级将在2024年7月20日左右公布。
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
分析师对Acumen Pharmicals(ABOS)的评级正确吗?
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a with a price target of $0.00 to $14.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $7.41, which is within the analyst's predicted range.
虽然评级是主观的,会发生变化,但最新的Acumen Pharmicals(ABOS)评级为a,目标股价为0.00美元至14.00美元。Acumen Pharmicals(ABOS)目前的交易价格为7.41美元,在分析师的预测区间内。